Gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that its research collaborators from Meharry Medical College will present promising preclinical data on Reqorsa Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer (SITC) meeting from 6-10 November 2024 in Houston, Texas.
The poster, titled 'TUSC2 Modulates Cancer Immune Responses', will highlight Reqorsa's ability to influence immune responses against cancer cells.
Reqorsa, Genprex's lead drug candidate, utilises the TUSC2 tumor suppressor gene delivered through the company's Oncoprex Delivery System, a lipid nanoparticle platform designed to target and deliver TUSC2 to cancer cells while sparing normal tissue. Preclinical studies demonstrated significantly higher TUSC2 uptake in cancer cells compared to normal cells.
Genprex is focused on developing therapies for cancer and diabetes. Reqorsa is currently being tested in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with both programs receiving FDA Fast Track Designation. The SCLC program also holds an FDA Orphan Drug Designation.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option